- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05040061
SkillJoy Clinical Trial (SkillJoy)
September 1, 2021 updated by: Skidmore College
SkillJoy Randomized Controlled Trial: Testing a Smartphone Intervention for Anxiety and Reinforcement
This study is a randomized controlled trial comparing a smartphone-delivered savoring intervention (SkillJoy) for Generalized Anxiety Disorder to an active treatment control.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The current study seeks to determine if the positivity intervention SkillJoy, a smartphone-based, ecological momentary intervention (EMI), can reduce worry and generalized anxiety disorder (GAD) symptoms, increase positive emotion and wellbeing, improve reinforcement and probabilistic learning, increase savoring and reduce kill-joy thinking, and decrease avoidance of negative emotional shifts relative to an active treatment control in a GAD sample.
Skills for generating positive emotion may reduce symptoms and increase well-being for those with GAD.
To test this approach, participants with GAD were randomly assigned to either a savoring treatment or a self-monitoring control.The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy.
SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
The active self-monitoring control EMI consisted of similar activities, but they all omitted savoring practices.
These activities included attending to any current thoughts and feelings, planning everyday activities, remembering and recording daily events, and anticipating important events.
Both EMIs were delivered by apps on participants' smartphones for seven days with 30th day follow-up.
Secondarily, the current study will assess differences between those with GAD and non-anxious controls on a computerized probabilistic reinforcement learning task and baseline savoring questionnaires.
Study Type
Interventional
Enrollment (Actual)
85
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Saratoga Springs, New York, United States, 12866
- Skidmore College
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Meet clinical criteria for Generalized Anxiety Disorder on the GAD-Q-IV and the GAD section of the Mini-International Neuropsychiatric Interview (MINI).
- Must be at least 18 years old to participate.
- Pregnant women will be allowed to participate.
Exclusion Criteria:
- They do not meet criteria for GAD on the GAD-Q-IV and the INI or do not fall one standard deviation below the subject pool mean on the GAD-Q-IV (i.e., they fall between these two scores).
- They are younger than 18 years of age.
- They do not speak English.
- They are adults unable to consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SkillJoy Intervention
The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy.
SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
|
The savoring treatment consisted of an ecological momentary intervention (EMI) for learning and practicing savoring skills-SkillJoy.
SkillJoy prompted participants to attend to positive aspects of the present moment, plan and engage in enjoyable activities, record and reflect on positive experiences, note events that turned out well, and look forward to positive events.
|
ACTIVE_COMPARATOR: Active Self-Monitoring Control Intervention
The active self-monitoring control EMI consisted of similar activities, but they all omitted savoring practices.
These activities included attending to any current thoughts and feelings, planning everyday activities, remembering and recording daily events, and anticipating important events.
|
The active self-monitoring control EMI prompted participants to notice and write current thoughts and feelings, plan the day's major activities, remember and write about their daily events, and anticipate upcoming important events.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pre- to Post-Trial and Pre-Trial to Follow-Up Change in The Penn State Worry Questionnaire
Time Frame: 8 day post-trial; 30th day follow-up
|
A 16-item self-report scale of the severity and frequency of worry.
Min.
score of 16 and maximum score of 80. Decreases in scores suggest a better outcome.
|
8 day post-trial; 30th day follow-up
|
Pre- to Post-Trial and Pre-Trial to Follow-Up Change in The Positive and Negative Affect Schedule, Expanded Form: Joviality Scale
Time Frame: 8 day post-trial; 30th day follow-up
|
An 8-item measure of positive emotions.
Min.
score of 8 and maximum score of 40.
Increases in scores suggest a better outcome.
|
8 day post-trial; 30th day follow-up
|
Pre- to Post-Trial and Pre-Trial to Follow-Up Change in The Savoring the Moment Subscale of the Savoring Beliefs Inventory
Time Frame: 8 day post-trial; 30th day follow-up
|
The SBI is a 14-item survey that measures beliefs about one's ability to savor.
The savoring the moment subscale measures savoring of present-moment emotional experience.
Min.
score of 1 and maximum score of 7. Increases in scores suggest a better outcome.
|
8 day post-trial; 30th day follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pre- to Post-Trial and Pre-Trial to Follow-Up Change in Responses to Positive Affect Scale: Dampening Subscale
Time Frame: 8 day post-trial; 30th day follow-up
|
Measure kill-joy thinking (a.k.a.
"dampening").
Participants rated eight dampening items on a 5-point scale.
Min.
score of 8 and maximum score of 32.
Decreases in scores suggest a better outcome.
|
8 day post-trial; 30th day follow-up
|
Pre- to Post-Trial and Pre-Trial to Follow-Up Change in The Prioritizing Positivity Scale
Time Frame: 8 day post-trial; 30th day follow-up
|
Measures the degree to which participants prioritized seeking positive experiences on six items with which participants either agree or disagree on a nine-point scale.
Min.
score of 6 and maximum score of 54.
Increases in scores suggest a better outcome.
|
8 day post-trial; 30th day follow-up
|
Pre- to Post-Trial and Pre-Trial to Follow-Up Change in The Life Orientation Test - Revised
Time Frame: 8 day post-trial; 30th day follow-up
|
Measures optimism.
It has 10 items rated on a four-point scale.
Min.
score of 6 and maximum score of 30.
Increases in scores suggest a better outcome.
|
8 day post-trial; 30th day follow-up
|
Pre- to Post-Trial and Pre-Trial to Follow-Up Change in The Beck Depression Inventory II
Time Frame: 8 day post-trial; 30th day follow-up
|
A 21-item self-report survey that measures the presence and severity of depressive symptoms.
Minimum score of 0 and maximum score of 63.
Decreases in scores suggest a better outcome.
|
8 day post-trial; 30th day follow-up
|
Pre- to Post-Trial and Pre-Trial to Follow-Up Change in Contrast Avoidance Questionnaire - Worry
Time Frame: 5 day mid-trial; 8 day post-trial; 30th day follow-up
|
Measures frequency, severity, and motivation to use worry to cope with negative shifts in emotion and benefit from positive shifts in emotion.
Min.
score of 30 and maximum score of 150.
Decreases in scores suggest a better outcome.
|
5 day mid-trial; 8 day post-trial; 30th day follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 17, 2018
Primary Completion (ACTUAL)
December 7, 2019
Study Completion (ACTUAL)
December 7, 2019
Study Registration Dates
First Submitted
August 24, 2021
First Submitted That Met QC Criteria
September 1, 2021
First Posted (ACTUAL)
September 10, 2021
Study Record Updates
Last Update Posted (ACTUAL)
September 10, 2021
Last Update Submitted That Met QC Criteria
September 1, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2108-974
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Any relevant de-identified IPD will be shared to other researchers upon reasonable, direct request.
IPD Sharing Time Frame
Data will be available at the time of reasonable request.
IPD Sharing Access Criteria
Data will be provided to 1) trained and credentialed researchers who 2) make a direct request to the authors with 3) a clearly-stated rationale and purpose for receiving the data that is considered relatively reasonable by the authors (e.g., to re-analyze a published statistical analysis).
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Anxiety Disorder
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
-
Xijing HospitalRecruitingGeneralized Anxiety DisorderChina
-
Sichuan Jishengtang Pharmaceutical Co., Ltd.Not yet recruitingGeneralized Anxiety Disorder
-
Hospital de Clinicas de Porto AlegreRecruitingGeneralized Anxiety DisorderBrazil
-
University of California, Los AngelesMedical University of South Carolina; Massachusetts General HospitalRecruitingGeneralized Anxiety DisorderUnited States
-
Shahid Beheshti University of Medical SciencesCompletedGeneralized Anxiety DisorderIran, Islamic Republic of
-
Dr. Nazanin AlaviOnline PsychoTherapy ClinicCompletedGeneralized Anxiety DisorderCanada
-
Laureate Institute for Brain Research, Inc.National Institute of Mental Health (NIMH)CompletedGeneralized Anxiety DisorderUnited States
-
The Canadian College of Naturopathic MedicineMassachusetts General Hospital; McGill University; Mitacs; Ekhagastiftelsen; Netherlands... and other collaboratorsActive, not recruitingGeneralized Anxiety DisorderCanada
Clinical Trials on SkillJoy Intervention
-
Biolux Research Holdings, Inc.TerminatedOrthodontic Tooth MovementCanada
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedColorectal Carcinoma | Healthy Subject | Health Status UnknownUnited States
-
University of FloridaCompletedSensitivityUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Institute on Minority Health and...RecruitingHuman Papillomavirus InfectionUnited States
-
Ohio State University Comprehensive Cancer CenterCompleted
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnCancer Survivor | Peripheral Sensory Neuropathy
-
Nottingham Trent UniversityUnknownOverweight and ObesityUnited Kingdom
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...American Cancer Society, Inc.Completed
-
Vanderbilt UniversityAgency for Healthcare Research and Quality (AHRQ)Completed